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Case Report
Pulmonary arterio-venous malformations in a
patient with a novel mutation in exon 10 of the
ACVRL1 gene
C. Vandenbriele1,2, K. Peerlinck1,2, T. de Ravel3, P. Verhamme1,2,
T. Vanassche1,2
1Center for Molecular and Vascular Biology, University of Leuven, Belgium, 2Vascular Medicine and
Haemostasis, University Hospitals Leuven, Belgium, 3Center for Human Genetics, University Hospitals Leuven,
Belgium
Mutations of the ACVRL1 gene are a cause of hereditary haemorrhagic telangiectasia (HHT) type 2. In this
case report, we present a patient with isolated pulmonary arterio-venous malformations (PAVMs) without
other diagnostic criteria for HHT and a novel mutation in exon 10 of the ACVRL1 gene. Other mutations in
exon 10 of ACVRL1 have been linked to the development of pulmonary artery hypertension, but PAVMs are
a rare manifestation of HHT associated with ACVRL1 mutations. A disrupted endothelial TGF-beta/BMP
signaling cascade underlies the pathogenesis of HHT, but the exact mechanism of the disease remains
unelucidated. In particular, the factors that influence the variable clinical presentation are not fully
understood.
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Introduction
Hereditary haemorrhagic telangiectasia (HHT), or
Rendu–Osler–Weber syndrome, is an autosomal
dominant multisystemic vascular dysplasia, with an
estimated prevalence of around one in 10.000
individuals.1,2 The clinical manifestations include
recurrent epistaxis, muco-cutaneous telangiectasia,
gastro-intestinal haemorrhage, and pulmonary, cere-
bral, and hepatic arterio-venous malformations.2
Individual patients may present with a wide range
of symptoms, and the clinical presentation may vary
considerably between affected members of the same
family. Because of the variable expression and
pleiotropy of HHT, diagnosis can be challenging,
particularly in younger individuals, as many of the
disease features become more pronounced with age.3
Therefore, diagnostic criteria have been formulated,
with a definitive diagnosis of HHT requiring the
presence of three or four of the typical clinical
manifestations (epistaxis, telangiectasia, visceral
manifestations, and positive family history).4
HHT is a genetically heterogeneous disorder. The
majority of cases are caused by mutations in either
the ENG gene on chromosome 9q encoding endoglin
(HHT type 1, OMIM 131195), or the ACVRL1 gene
on chromosome 12q encoding the Activin A receptor-
like kinase 1 (Alk1, HHT type 2, OMIM 601284).3,5,6
Case Report
A 53-year-old woman, with a medical history of
short-term memory loss, depression, and migraine,
was admitted to the emergency department due to
mild exercise-induced shortness of breath. Physical
examination revealed a slightly reduced arterial
oxygen saturation level, but was further unremark-
able. A contrast computed tomography scan of the
chest revealed various pulmonary arterio-venous
fistula (Fig. 1). Selective pulmonary angiography
confirmed these CT findings and the feeding arteries
were occluded during this procedure. Gadolinium-
enhanced magnetic resonance imaging of the brain —
performed due to memory loss — revealed diffuse old
ischaemic lesions without obvious cerebral vascular
malformations.
As there was no history of epistaxis or gastro-
intestinal bleeding, no known family members with
HHT, and no telangiectasia of the lips or tongue, the
present patient did not meet the full diagnostic
criteria for HHT. However, because of the presence
of the pulmonary arterio-venous malformations
(PAVMs), genetic analysis of the ENG gene and the
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ACVRL1 gene was performed, which demonstrated a
point mutation in exon 10 of the ACVRL1 gene
(c.1457A.T, p.K486M).
Discussion
We present a 53-year-old patient with PAVMs
associated with a novel mutation in exon 10 of the
ACVRL1 gene (c.1457A.T, p.K486M).
Mutations in the gene for the activin receptor-like
kinase 1 (ACVRL1), a type I serine-threonine kinase
receptor that is involved in the signaling of trans-
forming growth factor beta (TGF-beta) in endothelial
cells, are involved in the pathogenesis of HHT type 2.
Most mutations associated with HHT are found in
exon 3 — coding for the extracellular region — and in
exons 7 and 8, which code for the intracellular kinase
Figure 1 Pulmonary angiography (A) and CT findings (B, C). Axial and coronal contrast-enhanced CT scan (B, C) reveals
aneurysmal enlargement and arterio-venous malformation of the left lower lobe pulmonary artery, but no evidence of
intraluminal thrombi. These findings were confirmed by contrast-enhanced angiography (A).
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domain,7 whereas mutations in exon 10 account for
about 8% of the known mutations.7
Although ACVRL1 mutations interfere with the
regulation of angiogenesis,8 the detailed molecular
mechanism by which ACVRL1 deficiency leads to
vascular malformations still remains to be identified.7
This patient with pulmonary arterio-venous fistula
lacked the typical clinical features of HHT. Although
the severity, age of onset, and locations of the
vascular lesions are extremely variable from one
individual to another, almost 90% of HHT patients
have a history of epistaxis, and the vast majority of
patients exhibit at least two out of the four criteria.
Moreover, the presence of PAVM is less frequent
in HHT type 2, as compared to HHT type 1, which is
caused by mutations in the ENG gene encoding
Endoglin, a co-receptor for TGF-beta.9
Although PAVMs frequently remain undiagnosed
and asymptomatic, they may — as in this patient —
cause hypoxemia and dyspnea due to right-to-left
shunting. PAVMs may also result in bleeding
complications such as massive haemoptysis or
haemothorax, and central nervous system complica-
tions such as transient ischaemic attack or stroke due
to paradoxical embolism.10 An increased prevalence
of migraine has also been described.11 This patient
was found to have several diffuse ischaemic brain
zones, and also suffered from migraine.
Mutations in ACVRL1, and especially in exon 10,
are known to be associated with the development of
pulmonary artery hypertension in HHT type 2
patients.12 The principal known gene responsible for
familial and idiopathic pulmonary arterial hyperten-
sion is BMPR2, which encodes the bone morphoge-
netic protein receptor 2, and is a member of the TGF-
beta receptor superfamily. Upon binding of TGF-
beta, the formation of a heteromeric receptor
complex with ACVRL1 is required for the activation
of the intracellular signaling pathway, ultimately
leading to vascular differentiation as well as endothe-
lial proliferation.13–15
It remains unclear whether this patient has an
atypical and paucisymptomatic presentation of HHT
type 2, or whether the phenotype of isolated PAVM
is directly linked to the specific mutation described in
this report. Previous attempts to find genotype–
phenotype correlations in HHT patients have high-
lighted the variability of the clinical presentation,
even between affected members of the same family.
Therefore, other genetic and/or environmental fac-
tors are likely to influence both the type of vascular
malformation and the localization of the affected
vasculature. A better understanding of the mechan-
isms that protect certain vascular regions against the
effects of the disrupted TGF-beta signaling may offer
valuable clues for future therapeutic strategies.
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